Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

Clinical trial NCT07551414 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07551414
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Carcinoma)Leptomeningeal Metastasis EGFR-TKI Sensitizing Mutation Zorifertinib

Start date: 2026-05-30
Primary completion: 2027-05-30
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.